Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.
We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.
If you need assistance finding or assessing business development and/or partnership opportunities, contact us at firstname.lastname@example.org.
Lacerta Bio is seeking both parenteral and ophthalmic (topical) products for in-licensing on behalf of a US-based client. Key criteria are: > Products which can be developed via the 505(b)(2) regulatory process in the US > No specific therapeutic area or indication > Injectable could be infusion, prefilled syringe, or related presentation > Ophthalmics areRead More»
Our client has a Preclinical, highly selective mTOR 1/2 inhibitor available for licensing. This compound is a truly selective inhibitor of both mTORC1 and mTORC2, without PI3K activity or toxicity. With an excellent projected safety profile & oral administration, a number of indications within and outside oncology are possible. For more information, contact us via email by clicking on the linkRead More»
Our European client has developed a series of novel, patented salt forms of the most popular NSAIDS on the market (ibuprofen, naproxen, etc.). Clinical data demonstrates three important properties of these new compounds: Enhanced Safety – In multiple clinical studies, our client has shown that these novel salt forms have lower rates of severeRead More»
As a pharmaceutical scientist, the concept of “synthetic biology” sounds somewhat oxymoronic.
It’s true that our industry has been manipulating genes and cells to produce peptides, proteins, and other drugs/intermediates for decades.
But how about creating a cell line to make leather? Or clothing? Or building insulation?
Synthetic biology makes these ideas possible.
The authors take a very interesting approach. Instead of lecturing us on synthetic biology, they instead identify and interview 25-30 experts in their respective fields.
Some of the interviewees are familiar names, such as Craig Venter and George Church.
Importantly, the interview approach means a variety of subjects are covered in a very short, efficient manner.
If you’re unfamiliar with synthetic biology, then What’s Your Bio Strategy? by John Cumbers and Karl Schmieder is a great way to start.
One of the more interesting aspects of synthetic biology is the overlap between multiple disciplines, such as organism design, low-cost DNA synthesis, software, manufacturing, and others.
The final chapters on developing a bio strategy are also quite interesting.
You can pick up your own copy from Amazon or other fine book retailers.
What did we find interesting about 2017? What will happen in 2018? Our brief video summarizes our thoughts on the year that’s coming to a close, and also discusses what to keep an eye on in 2018.
As of this writing, there are 100 days until we’re wheels up and on our way to BIOEurope Spring in Amsterdam. Many believe it is too soon to think about a conference that is over three months away…or is it? This one gets complicated because of the intervening Winter Holidays and New Year. And
It’s amazing how months of preparation for a conference are realized in 4-5 intense days. From Sunday afternoon until the wee hours of Thursday morning, BIO-Europe in Berlin was jammed with 40 meetings, good meals, a few great receptions, a Buzz Session, two cigarettes, a few glasses of absinthe refreshment, and a new project or